| Literature DB >> 34874190 |
Mian Bao1, Naomi Hofsink1, Torsten Plösch1,2.
Abstract
A prominent health issue nowadays is the COVID-19 pandemic, which poses acute risks to human health. However, the long-term health consequences are largely unknown and cannot be neglected. An especially vulnerable period for infection is pregnancy, when infections could have long-term health effect on the child. Evidence suggests that maternal immune activation (MIA) induced by either bacteria or viruses presents various effects on the offspring, leading to adverse phenotypes in many organ systems. This review compares the mechanisms of bacterial and viral MIA and the possible long-term outcomes for the offspring by summarizing the outcome in animal LPS and Poly I:C models. Both models are activated immune responses mediated by Toll-like receptors. The outcomes for MIA offspring include neurodevelopment, immune response, circulation, metabolism, and reproduction. Some of these changes continue to exist until later life. Besides different doses and batches of LPS and Poly I:C, the injection day, administration route, and also different animal species influence the outcomes. Here, we specifically aim to support colleagues when choosing their animal models for future studies.Entities:
Keywords: fetal programming; lipopolysaccharide; long-term outcome; maternal infection; polyinosinic:polycytidylic acid
Mesh:
Substances:
Year: 2021 PMID: 34874190 PMCID: PMC8782664 DOI: 10.1152/ajpregu.00087.2021
Source DB: PubMed Journal: Am J Physiol Regul Integr Comp Physiol ISSN: 0363-6119 Impact factor: 3.619
Figure 1.A: activation of innate immune response by lipopolysaccharide (LPS) and polyinosinic:polycytidylic acid (Poly I:C) through Toll-like receptor (TLR) signaling pathway. LPS combines with LPS binding protein (LBP) and CD14 and delivers LPS-LBP to activate TLR4, initiating both MyD88-dependent pathway and Toll-IL-1 receptor domain-containing adapter-inducing interferon β (TRIF)-dependent pathway (21). 1) MyD88 activates TNF receptor associated factor-6 (TRAF6). In addition, TLR4 recruits TRIF-related adaptor molecule (TRAM) leading to TRAF6 activation. 2) TRAF6 drives the activation of transforming growth factor-β-activated kinase 1 (TAK1), which activates IκB kinase (IKK) complex and MAPK family members leading to the formation of NF-κB dimers and activator protein 1 (AP-1) transcription factor complex (21). NF-κB and AP-1 translocate into the nucleus to induce proinflammatory gene expression. 3) TLR3 is activated by Poly I:C, initiating TRIF-dependent pathway (22). TRIF directly interacts with TLR3 and dissociation leads to activation of TRAF3 and TRAF6 (23). 4) TRAF3 recruits IKK-related kinases TANK-binding kinase 1 (TBK1), IKKi, and IKKγ for Interferon regulatory factor 3 (IRF3) phosphorylation and dimer formation (23). 5) After translocation into the nucleus, NF-κB, AP-1, and IRF3 induce proinflammatory gene expression. NF-κB and AP-1 induce the expression of proinflammatory genes such as Il1b, Il6, and Tnfa (22). IRF3 induces the gene expression of type 1 IFN genes, such as Ifna and Ifnb (23). Retrieved from https://app.biorender.com/biorender-templates. B: immune response to corona virus through TLR signaling pathway. 6) Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) virus binds its cellular receptor ACE2 to enter airway epithelial cells (24). 7) TLR3, -7, -8, and -9 sense the virus in cells. Retinoic acid-inducible gene I (RIG-I) and melanoma differentiation-associated gene 5 (MDA5) recognize viral RNA and interact with mitochondrial antiviral-signaling protein (MAVS) (25). The activation of the TLRs and MAVS leads to the formation of NF-κB and IRFs dimers. The NF-κB and IRFs dimers translocate into the nucleus. 8) Gene expression of type 1 IFN genes and other proinflammatory genes are induced by NF-κB and IRF3 (25). ACE2, angiotensin converting enzyme 2. Retrieved from https://app.biorender.com/biorender-templates.
Outcomes of offspring after inducing MIA by LPS
| Animals | Dose and Injection Day | Outcomes | Notes | Refs. |
|---|---|---|---|---|
| BALB/c mice | 0.26 mg/kg | – Fetal brain damage | Melatonin administration prevents: fetal | ( |
| C57BL6/J mice | 120 μg/kg | – Fetal brain: | MIA induced by Poly I:C in parallel (see | ( |
| C57 mice | 75 μg/ kg | – Abnormal levels fat development, blood lipids, and glucose metabolism | MAPK pathway | ( |
| C57BL6/J mice | 100 μg/kg (total) | – Anxiety-like behaviors | ( | |
| C57BL6/J mice | 100 μg/kg (total) | – Social deficits | Reinjection, 40 mg/kg LPS, 8 wk offspring: | ( |
| C57BL6/J mice | 0.12 μg/g | – Memory deficits | Deleterious effects n-3 PUFA deficiency on | ( |
| C57BL6/J mice | 100 μg/kg | Intestinal injury | ( | |
| C57BL/6J mice | 20 μL | ♂ Offspring: | HPA axis signaling | ( |
| C57BL6/J mice | 100 µg/kg | – Intestinal injury | ( | |
| C57BL6/J mice | 20 mg/kg | ♂ Offspring: | TLR4 signaling | ( |
| CD-1 mice | 50 μg/dam | Alterations fetal brain: | ( | |
| CD-1 mice | 20 μg/kg | – ↓ Body weight | NF-κB pathway | ( |
| CD-1 mice | 25 μg in 100 μL PBS | – Fetal vessel resistance | ( | |
| ICR mice | 2 mg/kg | Morphological changes fetal brain | SIRT1/Nrf2 signaling pathway | ( |
| Sprague-Dawley rats | 1 mg/kg | – ↑ Fetal resorption rates | ( | |
| Sprague-Dawley rats | 0.79 mg/kg | – Hypertension | IL-6/Fli-1 pathway | ( |
| Sprague-Dawley rats | 0.79 mg/kg | – ↓ Body weight | High-fat diet: | ( |
| Sprague-Dawley rats | 100 µg/kg | – ↓ Motor activity | Age-dependent long lasting impact neur | ( |
| Sprague-Dawley rats | 1.5 mg/kg | – ↑ Anxiety-like behaviors | MIA induced by Poly I:C in parallel (see | ( |
| Wistar rats | 0.25 mg/kg | – Behavioral impairment | Ketamine injection PND54: | ( |
| Wistar rats | 0.5 mg/kg | – Endothelial dysfunction | Angiotensin II/NADPH oxidase pathway | ( |
| Wistar rats | 50 mg/kg | – ↓ Body weight | Fulvestrant treatment restored outcomes | ( |
| Wistar rats | 50 μg/kg | – Delayed reproductive maturity | Postnatal estradiol and testosteroneantagonist treatment | ( |
| Wistar rats | 500 μg/kg | – Microbiome abundance: | Abnormal brain-gut-microbiota | ( |
GD, gestational days; LPS, lipopolysaccharide; MIA, maternal immune activation; Poly I:C, polyinosinic:polycytidylic acid; PUFA, polyunsaturated fatty acid; TLR4, Toll-like receptor 4 ↑, increase; ↓, decrease; ♂, male; ♀, female.
Outcomes of offspring after inducing MIA by Poly I:C
| Animals | Dose and Injection Day | Outcomes | Notes | Refs. |
|---|---|---|---|---|
| BALB/c mice | 20 mg/kg | – Differences in species richness microbiome | Differential bacterial findings | ( |
| C57BL/6 mice | 20 mg/kg | Preferential to Th17 cell differentiation of lymphocytes | Adaptive immune system | ( |
| C57BL/6J mice | 20 mg/kg | – Behavioral impairments | Lower complex I activity | ( |
| C57BL/6J mice | 5 mg/kg | – ↓ Growth and sensorimotor development | MIA induced by LPS in parallel (see | ( |
| C57BL6/J mice | 5 mg/kg | – Juvenile cortex: | Early epigenetic changes | ( |
| C57BL/6J mice | 5 mg/kg | Adult frontal cortex: | Chronic paliperidone: | ( |
| C57BL/6J mice | 5 mg/kg | – Neuroanatomical alterations | ( | |
| C57BL/6N mice | 5 mg/kg | Hypomethylation of adult brain | n-3 PUFA intervention | ( |
| C57BL/6J mice | 20 mg/kg | – Activation of local circuit interneurons adult brain | Alterations in flow of signals | ( |
| C57BL/6J mice | 20 mg/kg | – Neonate immune organs and brain: | ( | |
| C57BL/6J mice | 20 mg/kg | – ♂ Offspring: | ( | |
| C57BL/6J mice | 20 mg/kg | Fetal and placental sex influenced: | Gene pathways: | ( |
| C57BL/6 mice | 20 mg/kg | – ↑ CCL5 and CXCL10 fetal brain | JNK signaling | ( |
| C57BL/6J mice | 20 mg/kg | – Neonate immune organs and brain: | ( | |
| C57BL/6J mice | 5 mg/kg/mL | Fetal brains: | Gene pathways: | ( |
| CD-1 mice | 5 mg/kg | – ♂ Offspring: | NRG-ErbB signaling pathway | ( |
| Sprague-Dawley rats | 10 mg/kg | – Age-related behavioral and neuro-inflammatory changes | ( | |
| Sprague-Dawley rats | 10 mg/kg | Fetal brains: | ( | |
| Sprague-Dawley rats | 10 mg/kg | – Depressive-like behavior | NEDD4/Rap2A signaling | ( |
| Sprague-Dawley rats | 20 mg/kg | – ↑ Anxiety-like behaviors | MIA induced by LPS in | ( |
| Wistar rats | 4 mg/kg | ♂ Offspring: | Schizophrenia-like | ( |
| Wistar rats | 5 mg/kg | Fetal brains: | Gene pathways: | ( |
| Wistar rats | 10 mg/kg | – ↓ Litter size depending on Poly I:C supplier | Outcome depending on | ( |
GD, gestational days; LPS, lipopolysaccharide; MIA, maternal immune activation; Poly I:C, polyinosinic:polycytidylic acid; PUFA, polyunsaturated fatty acid; TLR3, Toll-like receptor 3. HPA, hypothalamic-pituitary-adrenal; PDTC, pyrrolidine dithiocarbamate; mPFC, medial prefrontal cortex; GI, Gastrointestinal; CAMs, cell adhesion molecules; PND, postnatal day; CCL5, chemokine (C-C motif) ligand 5; CXCL10, C-X-C motif chemokine ligand 10; ↑, increase; ↓, decrease; ♂, male; ♀, female.
Figure 2.Overview of offspring outcomes from lipopolysaccharide (LPS) and polyinosinic:polycytidylic acid (Poly I:C) maternal immune activation (MIA) dams.